Comparison of Efficacy and Safety of Statin–Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies
Published version of a preprint
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“First, the inclusion of other lipid-lowering agents, such as ezetimibe (which inhibits cholesterol absorption) or PCSK9 inhibitors (which prevents the degradation of LDL receptors), along with statin therapy has been associated with a greater decrease in cholesterol levels.[75][76][77]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Grundy, S. M., Cleeman, J. I., Bairey Merz, C. N., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.001 · Cited by 1,550
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Kotseva, K., Wood, D., Backer, G. D., Bacquer, D. D., Pyörälä, K., Keil, U., & EUROASPIRE Study Group (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283294b1d · Cited by 812
Tsujita, K., Sugiyama, S., Sumida, H., Shimomura, H., Yamashita, T., Yamanaga, K., Komura, N., Sakamoto, K., Oka, H., Nakao, K., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.065 · Cited by 459 · cited 1×
“Another study reported that the combination of statins and ezetimibe showed greater coronary plaque regression than did statin monotherapy in patients with acute coronary syndrome, but weaker coronary plaque regression was observed in patients with diabetes than in those without diabetes in the subanalysis [41, 42].”
ResultGiugliano, R. P., Cannon, C. P., Blazing, M. A., Nicolau, J. C., Corbalán, R., Špinar, J., Park, J.-G., White, J. A., Bohula, E. A., & Braunwald, E. (2018) · Circulation · doi:10.1161/circulationaha.117.030950 · Cited by 427
Metabolic Syndrome: Clinical and Policy Implications of the New Silent Killer
Sherling, D. H., Perumareddi, P., & Hennekens, C. H. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416686187 · Cited by 268 · cited 1×
“Dyslipidemia, along with insulin resistance, obesity, and hypertension, is a metabolic syndrome-related factor that causes atherosclerosis and increases the risk of cardiovascular diseases (CVDs) and stroke [1].”
BackgroundStatins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis
Erqou, S., Lee, C. C., & Adler, A. I. (2014) · Diabetologia · doi:10.1007/s00125-014-3374-x · Cited by 126
Leiter, L. A., Betteridge, D. J., Farnier, M., Guyton, J. R., Lin, J., Shah, A., Johnson‐Levonas, A. O., & Brudi, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01383.x · Cited by 84
Research works printed but not linked: 37
- Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97. https://doi.org/10.1001/jama.285.19.2486 · DOI · Paper page
- Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96. · DOI · Paper page
- Darkes MJ, Poole RM, Goa KL. Ezetimibe. Am J Cardiovasc Drugs. 2003;3:67–76 (discussion 77–8). · DOI
- Nubaumer B, Glechner A, Kaminski-Hartenthaler A, Mahlknecht P, Gartlehner G. Ezetimibe-statin combination therapy. Dtsch Arztebl Int. 2016;113:445–53.
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. · DOI · Paper page
- Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29. · DOI · Paper page
- Mantel N, Henszel W. Statistical aspects of the analysis of data from retrospective sties of diseases. J Natl Cancer Inst. 1959;22:719–48.
- DerSimonian R, Larid N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. · DOI · Paper page
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometircs. 1994;50:1088–101. · DOI · Paper page
- Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34. · DOI · Paper page
- Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, Gumbiner B. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin. 2004;20:1437–45. https://doi.org/10.1185/030079904x2321. · DOI
- Gaudiani LM, Lewin A, Meneghini L, Perevozskaya I, Plotkin D, Mitchel Y, Shah S. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab. 2005;7:88–97. https://doi.org/10.1111/j.1463-1326.2004.00420.x. · DOI · Paper page
- Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diabetes Vasc Dis Res. 2006;3:93–102. https://doi.org/10.3132/dvdr.2006.020. · DOI
- Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc. 2006;81:1579–88. · DOI
- Constance C, Westphal S, Chung N, Lund M, Sisk CM, Johnson-Levonas AO, et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2007;9:575–84. · DOI · Paper page
- Settergren M, Böhm F, Rydén L, Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycemia and coronary artery disease. Eur Heart J. 2008;29:1753–60. https://doi.org/10.1093/eurheartj/ehn166. · DOI
- Polis AB, Abate N, Catapano AL, Ballantyne CM, Davidson MH, Smugar SS, Tershakovec AM. Affiliations expand Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by national cholesterol education program risk category. Metab Syndr Relat Disord. 2009;7:601–10. https://doi.org/10.1089/met.2009.0009. · DOI
- Bardini G, Giorda CB, Pontiroli E, Le Grazie C, Rotella CM. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol. 2010;9:20. https://doi.org/10.1186/1475-2840-9-20. · DOI
- Ruggenenti P, Cattaneo D, Rota S, Iliev I, Parvanova A, Diadei O, et al. Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care. 2010;33:1954–6. https://doi.org/10.2337/dc10-0320. · DOI
- Kawagoe Y, Hattori Y, Nakano A, Aoki C, Tanaka S, Ohta S, et al. Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. Endocr J. 2011;58:171–5. · DOI
- Uemura Y, Watarai M, Ishii H, Koyasu M, Takemoto K, Yoshikawa D, et al. Atorvastatin 10mg plus ezetimibe 10mg compared with atorvastatin 20mg: Impact on the lipid profile in japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol. 2012;59:50–6. · DOI
- Vaverkova H, Farnier M, Averna M, Missault L, Viigimaa M, Dong Q, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. Cardiovasc Ther. 2012;30:61–74. https://doi.org/10.1111/j.1755-5922.2010.00181.x. · DOI
- Rosen JB, Jimenez JG, Pirags V, Vides H, Massaad R, Hanson ME, et al. Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects. Lipids Health Dis. 2013;12:103. https://doi.org/10.1186/1476-511X-12-103. · DOI
- Torimoto K, Okada Y, Mori H, Hajime M, Tanaka K, Kurozumi A, et al. Efficacy of combination of ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 2013;12:137. https://doi.org/10.1186/1476-511X-12-137. · DOI
- Villegas-Rivera G, Román-Pintos LM, Cardona-Muñoz EG, Arias-Carvajal O, Rodríguez-Carrizalez AD, Troyo-Sanromán R, et al. Effects of ezetimibe/simvastatin and rosuvastatin on oxidative stress in diabetic neuropathy: a randomized, double-blind, placebo-controlled clinical trial. Oxid Med Cell Longev. 2015;2015: 756294. https://doi.org/10.1155/2015/756294. · DOI
- Sakamoto K, Kawamura M, Watanabe T, Ashidate K, Kohro T, Tanaka A, et al. Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids Health Dis. 2017;16:122–4. https://doi.org/10.1186/s12944-017-0508-4. · DOI
- El-Tamalawy MM, Ibrahim OM, Hassan TM, El-Barbari AA. Effect of combination therapy of ezetimibe and atorvastatin on remnant lipoprotein versus double atorvastatin dose in egyptian diabetic patients. J Clin Pharmacol. 2018;58:34–41. https://doi.org/10.1002/jcph.976. · DOI
- Menotti A, Keys A, Blackburn H, Kromhout D, Karvonen M, Nissinen A, et al. Comparison of multivariate predictive power of major risk factors for coronary heart diseases in different countries: results from eight nations of the Seven Countries Study, 25-year follow-up. J Cardiovasc risk. 1996;3:69–75. · DOI
- Gotto AM Jr. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation. 2001;103:2213–8. · DOI
- Miao XY, Liu HZ, Jin MM, Sun BR, Tian H, Li J, et al. A comparative meta-analysis of the efficacy of statin-ezetimibe co-therapy versus statin monotherapy in reducing cardiovascular and cerebrovascular adverse events in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2019;23:2302–10. https://doi.org/10.26355/eurrev_201903_17279. · doi:10.26355/eurrev_201903_17279
- Lally SE, Owens D, Tomkin GH. Sitosterol and cholesterol in chylomicrons of type 2 diabetic and non-diabetic subjects: the relationship with ATP binding cassette proteins G5 and G8 and niemann-pick C1-like 1 mRNA. Diabetologia. 2007;50:217–9. https://doi.org/10.1007/s00125-006-0504-0. · DOI
- Lally S, Owens D, Tomkin GH. Genes that affect cholesterol synthesis, cholesterol absorption, and chylomicron assembly: the relationship between the liver and intestine in control and streptozotosin diabetic rats. Metabolism. 2007;56:430–8. · DOI
- Tomkin GH. The intestine as a regulator of cholesterol homeostasis in diabetes. Atheroscler Suppl. 2008;9:27–32. https://doi.org/10.1016/j.atherosclerosissup.2008.05.012. · DOI
- Koichiro F, Kenshi Y, Suguru N, Hideki S, Takuro Y, Koichi N, et al. Effects of statin plus ezetimibe on coronary plaques in acute coronary syndrome patients with diabetes mellitus: sub-analysis of PRECISE-IVUS trial. J Atheroscler Thromb. 2021;28:181–93. https://doi.org/10.5551/jat.54726. · DOI
- Wu H, Shang H, Wu J. Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2018;60:229–39. https://doi.org/10.1007/s12020-018-1541-4. · DOI
- Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Cren AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375:735–42. https://doi.org/10.1016/S0140-6736(09)61965-6. · DOI · Paper page
- Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87:98–107. https://doi.org/10.1016/j.diabres.2009.10.008. · DOI · Paper page
Cited by
Rakhshanda, S., Briggs, N. E., Rhee, J., Rye, K.-A., Liaw, S.-T., & Jonnagaddala, J. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag175 · Cited by 6
Metadata
- Authors
- Shin, K.-H., & Choi, H. D.
- ORCID
- Choi, Hye Duck
- Venue
- American Journal of Cardiovascular Drugs
- Published
- 2021-12-20
- Volume
- 22
- Issue
- 4
- Pages
- 395-406
- ISSN
- 1175-3277
- 1179-187X
- Cited by
- 12
- References
- 10
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Funders
- Yeungnam University (2020 Yeungnam University Research Grant)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.